Amicus Briefs: Louisiana v. FDA

Nationwide Threat to Medication Abortion
  • Case Status Active
  • Last Updated
  • Issue
    • Abortion
  • Place
    • Louisiana
    • United States

Louisiana v. FDA is one of several court cases through which the anti-abortion movement is attacking access to medication abortion.

On February 24, 2026, a U.S. District Court held a hearing on Louisiana’s emergency request to reinstate the medically unnecessary in-person dispensing requirement for mifepristone nationwide. To oppose these efforts, hundreds of organizations submitted amicus curiae (“friend of the court”) briefs.

Summary

Summary

As listed below, a broad range of experts, including the Center for Reproductive Rights, have filed amicus briefs with the U.S. District Court for the Western District of Louisiana in Louisiana v. FDA. These briefs underscore the safety and efficacy of the medication abortion drug at issue (mifepristone) and urge the court to reject the state’s attempts to reinstate medically unnecessary restrictions on mifepristone nationwide.

Submitted by leading medical and health organizations, former government officials, reproductive health, rights and justice advocates, and many other experts, the briefs argue that accepting the state’s arguments would upend the FDA’s evidence-based decision to lift the in-person dispensing requirement; harm patient health; and interfere with provider-patient decision-making. In addition, several briefs outline mifepristone’s proven safety and efficacy since it was first approved more than two decades ago.

Below are the amicus briefs that have been filed in this case supporting access to medication abortion.

U.S. District Court, 2026

U.S. District Court, Western District of Louisiana, Lafayette Division, 2.20.26